UOC
PGNX

UBS O'Connor’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

UBS O'Connor’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-50,000
Closed -$204K – 575
2014
Q1 		$204K Buy
+50,000
New +$256K ﹤0.01% 400
2013
Q3 		– Sell
-318,191
Closed -$1.42M – 604
2013
Q2 		$1.42M Buy
+318,191
New +$1.43M 0.03% 342

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS O'Connor's PGNX Position: Q2 2014 in Review

UBS O'Connor sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2014, closing a stake of 50,000 shares — an estimated $204K sold.

UBS O'Connor first reported a position in PGNX in Q2 2013 and held it in 2 quarters. The position peaked at $1.42M in Q2 2013. 76 funds tracked by Wall St. Rank hold PGNX as of Q2 2014.

  • UBS O'Connor reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • UBS O'Connor sold 50,000 Progenics Pharmaceuticals Inc shares in Q2 2014, an estimated $204K.
  • UBS O'Connor first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • UBS O'Connor's Progenics Pharmaceuticals Inc position peaked at $1.42M in Q2 2013.
  • 76 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2014.

Based on UBS O'Connor's 13F filing for Q2 2014, filed 15 Aug 2014.